New referral to EPO over hidden internal structure or composition in prior art

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

New referral to EPO over hidden internal structure or composition in prior art

Sponsored by

inspicos-400px recrop.jpg
molecules-3713741.jpg

Edward Farrington of Inspicos reports that guidance is being sought from the EPO Enlarged Board of Appeal three decades after a decision on the analysis of complex products

Patentees and patent applicants before the EPO are occasionally faced with prior art – for example, products which have been put on the market – the internal structure or composition of which is not clear without further investigation. In mechanical fields, such products might be devices or apparatuses which have to be disassembled or broken up to determine the contents. In the chemical field, such products might be polymers or similar chemical compositions, which are difficult or impossible to analyse.

Enlarged Board decision G 1/92 (OJ EPO May 1993) considered what “hidden properties” such products actually disclosed. Decision G 1/92 found that “[t]he chemical composition of a product is state of the art when the product as such is available to the public and can be analysed and reproduced by the skilled person… Where it is possible for the skilled person to discover the composition or the internal structure of the product and to reproduce it without undue burden, then both the product and its composition or internal structure become state of the art.”

Although decision G 1/92 is regularly relied upon by parties before the EPO, it did not clearly explain the meaning of the phrases “reproduce without undue burden”, “available to the public”, and “can be analysed”. Divergent case law has developed since G 1/92: some decisions requiring a high level of certainty when analysing hidden properties, others requiring a less complete analysis, and still other decisions excluding such disclosures from the state of the art altogether.

The Enlarged Board of Appeal (EBA) has therefore been asked to clarify some of the issues remaining after G 1/92 in a new referral, G 1/23.

In particular, the EBA will consider whether a marketed product can be excluded from the prior art if its composition or internal structure cannot be analysed. It will also consider whether technical information about a marketed product is state of the art, regardless of whether the composition or internal structure of the product can be analysed. The EBA is also being asked to clarify which criteria apply in determining whether the composition or internal structure of a product could be analysed and reproduced without undue burden.

It is hoped that decision G 1/23 will provide guidance as to which level complex products such as polymers must be analysed if they are to be considered state of the art.

more from across site and SHARED ros bottom lb

More from across our site

Amita Haylock discusses building an integrated Asia practice as clients increasingly demand that firms combine IP, technology and data expertise
François Pochart, Grégoire Desrousseaux and Lionel Martin, long-standing figures in the firm’s patent litigation team, are set to help launch a Paris-based litigation offering
The Unitary Patent has passed 100,000 registrations, but new data raises the question of whether 30% uptake is a ceiling or a staging post for further growth, say Michael Nielsen and Darren Smyth of EIP and Andrew Samm at Patently
The new generation of in-house IP leaders want commercial judgment, accessibility and flexibility, with AI raising expectations around both fees and delivery
The firm launched a San Diego office earlier this month, but California investment and expansion is far from complete
The industry’s response to AI requires an unfamiliar ingredient as firms battle to shape their futures
The firm is looking beyond replacing recently departed talent, betting instead on senior leaders to strengthen and expand its patent litigation platform
Olga Partington, director in Sterne Kessler’s biotechnology and chemical practice group, shares why a patent's vulnerability peaks when it is young, rather than when it is most valuable, under the PTAB's new framework
IP experts gathered in San Francisco last week to discuss the changing global SEP landscape and new licensing models for AI infrastructure
SKW Schwarz partner Daniel Kendziur explains how new green claims rules are changing his workload and bringing him into direct contact with marketing, PR and government affairs teams
Gift this article